<DOC>
	<DOC>NCT01984489</DOC>
	<brief_summary>SHR117887 is a new dipeptidyl peptidase(DPP)-4 inhibitor. This study aims to evaluate the efficacy and safety of SHR117887 in combination therapy with Metformin in patients with Type 2 Diabetes in Metformin monotherapy Who have Inadequate Glycemic Control</brief_summary>
	<brief_title>Efficacy and Safety Study of SHR117887 in Combination With Metformin in Patients With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients diagnosed with type 2 diabetes mellitus Patients have been treated with metformin for at least 8 weeks and be on a stable dose of at least 1500mg daily prior to the screening visit HbA1C：≥7.5% and ≤11.0% at screeing visit and at the end of runin period Age:≥20 and ≤70 years BMI(body mass index):≥20 and ≤35 kg/m2</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>SHR117887, Metformin,combination,PhaseII</keyword>
</DOC>